Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Heron Therapeutics ( (HRTX) ) has issued an update.
On June 12, 2025, Heron Therapeutics held its Annual Meeting of Stockholders where key decisions were made, including the election of six directors and the ratification of Withum Smith+Brown, PC as the independent accounting firm for 2025. Stockholders also approved executive compensation for 2024 and decided to conduct annual advisory votes on executive pay, aligning with the company’s recommendations. These decisions reflect the company’s commitment to governance and transparency, potentially impacting its stakeholder relationships positively.
The most recent analyst rating on (HRTX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Heron Therapeutics stock, see the HRTX Stock Forecast page.
Spark’s Take on HRTX Stock
According to Spark, TipRanks’ AI Analyst, HRTX is a Neutral.
Heron Therapeutics’ overall score is mainly impacted by its financial instability and valuation challenges, despite positive developments in earnings and corporate strategy. The technical outlook remains neutral, with mixed indicators.
To see Spark’s full report on HRTX stock, click here.
More about Heron Therapeutics
Heron Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing treatments for patients suffering from cancer and pain management. The company is known for its innovative therapies aimed at improving the quality of life for patients undergoing chemotherapy or dealing with postoperative pain.
Average Trading Volume: 1,463,321
Technical Sentiment Signal: Sell
Current Market Cap: $309.7M
For a thorough assessment of HRTX stock, go to TipRanks’ Stock Analysis page.